Insider buying last 90 days
No open-market insider purchases were filed for STE in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every STE insider filing, plotted on the chart in Gekko.Open STE in Gekko
NYSE: STE
STERIS plc (Ireland) (STE) Stock Analysis & Forecast
Sep 28 close
$211.00+2.07 (+1.0%)
Gekko Brief
AI summarySTERIS shares have traded near their 52-week low in recent weeks, with the stock closing at $205.04 on 18 September before recovering toward $211.00. The move follows Argus lowering its price target twice, first to $240.00 and then to $230.00, alongside coverage of the company's $600 million investment in a North Carolina manufacturing and distribution campus and its participation in the Morgan Stanley Healthcare Conference with CEO Dan Carestio. A quarterly dividend of $0.69 was also paid during the period.
The stock closed at $211.00, up 1%, but remains below both its 50-day average of $224.16 and 200-day average of $229.07, with the 50-day below the 200-day. Over the past year the stock is down 13.6%, and the six-month return stands at -3.8%. The GekkoIndex reads 65.4, placing STE in the Accumulation zone, while the price sits 12.1% below the Gekko Fair Value of $240.06.
The next earnings report is scheduled for 4 November 2026, 36 days out and beyond a typical 20-trading-day holding window. No insider, Congress or unusual options activity appears in the recent windows. Seasonality data shows the next 20 trading days have averaged a 0.2% return over 5 years, rising in 2 of those years. Analyst coverage currently shows 3 buy and 1 hold ratings among 4 firms, with a consensus target of $263.12.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
STERIS plc (Ireland) price vs fair value
Close $211.00200-day averageGekko Fair Value $240.06
STERIS plc (Ireland) quick facts
- Market cap
- $20.56B
- P/E ratio
- 25.7
- Forward P/E
- 19.2
- EPS, TTM
- $8.14
- Revenue, TTM
- $6.04B
- Profit margin
- 13.3%
- Dividend yield
- 1.20%
- Beta
- 0.91
- Volume
- 493,647 avg 641,442
- 1-year return
- −13.6%
- Typical daily move
- ±1.9%
- Typical 20-day move
- ±4.4%
- 50-day average
- $224.16
- 200-day average
- $229.07
- Next earnings
- Nov 4 before open
- Shares outstanding
- 97.50M
STERIS plc (Ireland) swing-trade checklist
STERIS plc (Ireland) scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendheadwind
Below 50 and 200-day
Close $211.00 is below the 50-day ($224.16) and 200-day ($229.07) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
65.4, Accumulation
Reading 65.4 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
12.1% below
Price is 12.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 36 days
Next report Nov 4, 2026, 36 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+0.2% on average
From this point in the calendar, the next 20 trading days averaged +0.2% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
STERIS plc (Ireland) stock chart and price history
STERIS plc (Ireland) closed at $211.00 on Sep 28, 2026, −13.6% over the past year, inside a 52-week range of $195.14 to $269.44.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −9.4%
- 3 months
- −1.1%
- 6 months
- −3.8%
- 1 year
- −13.6%
The full STE chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open STE in Gekko
Follow STERIS plc (Ireland) through every session
Put STE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track STE in GekkoFree for 7 days. No credit card required.
About STERIS plc (Ireland)
STERIS plc focuses on keeping medical and laboratory settings free of contamination, offering goods and services tied to infection control across the United States, Ireland, and other markets. Its offerings span cleaning chemicals, products that confirm sterility, systems for reprocessing endoscopes automatically, and equipment such as surgical tables and lighting, along with tools that connect devices within a facility.
Work at the company is divided into three areas: Healthcare, Applied Sterilization Technologies, and Life Sciences. On top of selling equipment, STERIS handles upkeep of machines, repairs instruments, and sterilizes items under contract for firms that make medical devices and pharmaceutical products.
The company is incorporated in Ireland, and investors can trade its stock on the NYSE, where it carries the ticker STE.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- steris.com
STERIS plc (Ireland) GekkoIndex: the smart money zone
STERIS plc (Ireland)’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 65.4, in the Accumulation zone, down 10.1 points over five sessions.
65.4Accumulation
Down 10.1 points over five sessions, from the Buying zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 35 | +0.2% | +8.1% | ||
| Accumulation (current zone) | 251 | +0.2% | +0.8% | ||
| Neutral | 357 | 0.0% | −0.7% | ||
| Distribution | 28 | −1.8% | −2.9% | ||
| Selling | 1 | Too few readings yet | |||
Average STE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the STE price, zone by zone.Track STE in Gekko
Is STERIS plc (Ireland) stock overvalued? Gekko Fair Value
STERIS plc (Ireland) trades 12.1% below Gekko Fair Value of $240.06, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what STERIS plc (Ireland) shares are worth, recalculated every trading day.
$240.06
Gekko Fair Value, Sep 26, 2026
12.1% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open STE in Gekko
STERIS plc (Ireland) insider and Congress trading
No open-market insider purchases were filed for STERIS plc (Ireland), and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in STE were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for STE, plotted on the chart in Gekko.Open STE in Gekko
Buybacks
STERIS plc (Ireland) has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $115.5M
- As a share of market cap
- 0.56%
- Trailing four quarters
- $340.4M
From company filings.
STERIS plc (Ireland) earnings: next date and track record
STERIS plc (Ireland) reports on Nov 4, 2026, before the open (36 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected before the open, 36 days away
- EPS estimate
- $2.67
- Revenue estimate
- $1.56B
6 of 8reports beat the EPS estimate
±4.5%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Feb 3, 2026 AI summary
- What they said
- STERIS reported solid Q3 FY2026 results with revenue up 9% as-reported and 8% constant currency organic growth driven by volume and pricing. Gross margin declined 70 bps to 43.9% due to tariffs and inflation; EBIT margin fell 40 bps to 22.9% after gross margin pressure partially offset by operating discipline. Adjusted EPS rose 9% to $2.53. Segment performance: Healthcare organic revenue +8% (services +11%, consumables +8%, capital +7%) with backlog >$400M; AST organic +8% (services +9%, capital +103%) with margins up; Life Sciences organic +5% (consumables +11%), backlog >$100M. Tariffs impacted results (~$16M in Q3; $55M annual run rate). Capital expenditure YTD $278.8M; free cash flow YTD improved; gross debt $1.9B, gross debt/EBITDA ~1.2x. Company maintained fiscal 2026 outlook. Management noted macro improvements in life sciences, resilient healthcare capital demand, ongoing tariff mitigation, and committed to EMEA go-to-market changes. Q&A reaffirmed outlook, addressed tariffs, backlog, M&A discipline, cash flow conservatism, and AST services seasonality.
- Guidance
- Management said they are maintaining fiscal 2026 outlook, including tariff assumptions (annual run rate ~$55M) and constant currency organic revenue guidance of 7%-8% for FY2026. No new numeric FY2027 guidance was provided.
- Risks flagged
- Tariff impacts (metals and capital equipment mix) materially pressured gross margin (~$16M in Q3; $55M annual run rate). Inflation and increased tariffs, labor and energy costs, unfavorable mix from capital growth, and potential macro/regulatory changes (pharma pricing/regulatory) were cited as headwinds.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Feb 3, 2026 | $2.53 est $2.53 | $1.50B est $1.48B | 0.0% |
| Nov 5, 2025 | $2.47 est $2.35 | $1.46B est $1.43B | +7.5% |
| Aug 6, 2025 | $2.34 est $2.26 | $1.39B est $1.36B | +5.5% |
| May 14, 2025 | $2.74 est $2.60 | $1.48B est $1.47B | +6.8% |
| Feb 5, 2025 | $2.32 est $2.32 | $1.37B est $1.38B | +2.8% |
| Nov 6, 2024 | $2.14 est $2.13 | $1.33B est $1.33B | −5.2% |
| Aug 6, 2024 | $2.14 est $1.98 | $1.28B est $1.27B | −1.8% |
| May 8, 2024 | $2.58 est $2.35 | $1.42B est $1.41B | +6.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
STERIS plc (Ireland) stock forecast and analyst price targets
Analysts’ average 12-month price target for STERIS plc (Ireland) is $263.12, +24.7% from the last close, from 4 firms rating the stock in the last 90 days.
$263.12consensus 12-month target, +24.7% from the last close
Now $211.00Avg $263.12
Low $269High $275
Each firm’s latest rating in the last 90 days: 4 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 17 | KeyBanc | $269 | +27.5% |
| Aug 7 | Piper Sandler | $275 | +30.3% |
| Aug 7 | UBS | $270 | +28.0% |
| Aug 6 | Needham | — | — |
| Jul 28 | UBS | $275 | +30.3% |
+0.8%average 20-day move after past Accumulation readings
+0.2%average move over the next 20 trading days in the last 5 years
±1.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
STERIS plc (Ireland) seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, STERIS plc (Ireland) averaged +0.2% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.4% | 3 of 5 |
| Next 10 trading days | −0.2% | 3 of 5 |
| Next 15 trading days | −0.1% | 1 of 5 |
| Next 20 trading days | +0.2% | 2 of 5 |
| Next 30 trading days | +0.5% | 3 of 5 |
For scale, STE’s typical 20-trading-day move in either direction is about 4.4%.
STERIS plc (Ireland) market cap and key statistics
STERIS plc (Ireland)’s market cap is $20.56B, with a P/E ratio of 25.7 and revenue of $6.04B over the last twelve months.
Valuation
- Market cap
- $20.56B
- P/E ratio
- 25.7
- Forward P/E
- 19.2
- EPS, TTM
- $8.14
- Gekko Fair Value
- $240.06
Trading
- Volume
- 493,647
- Avg volume, 20 days
- 641,442
- 52-week high
- $269.44
- 52-week low
- $195.14
- Shares outstanding
- 97.50M
Financials
- Revenue, TTM
- $6.04B
- Profit margin
- 13.3%
- Return on equity
- 11.4%
- Quarterly earnings growth, YoY
- +14.0%
Risk and income
- Beta
- 0.91
- Typical daily move
- ±1.9%
- Typical 20-day move
- ±4.4%
- Dividend yield
- 1.20%
STERIS plc (Ireland) stock news this week
Coverage of STERIS plc (Ireland) this week reads neutral: 1 positive, 5 neutral and 2 negative headlines.
- STERIS stock at USD 209.34 on September 28, 2026AD HOC NEWS, Sep 28
- STERIS stock last at USD 208.44, down 0.16 percent in New York tradingAD HOC NEWS, Sep 25
- STERIS stock trades lower before the bell after a 0.6 percent dropAD HOC NEWS, Sep 25
- STERIS plc (Ireland) (STE) Stock forecastsYahoo Finance Singapore, Sep 24
- Steris plc stock heads into the open after closing at USD 208.79AD HOC NEWS, Sep 24
- Steris plc stock holds near its yearly lowAD HOC NEWS, Sep 23
STERIS plc (Ireland) peers
STERIS plc (Ireland)’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 23.7% above |
| ABTAbbott Laboratories | Accumulation | 15.0% below |
| DHRDanaher | Distribution | 10.2% above |
| ISRGIntuitive Surgical | Neutral | 17.0% above |
| MDTMedtronic | Accumulation | 24.1% below |
| SYKStryker | Accumulation | 14.1% below |
A peer links to its own page where one exists.
STERIS plc (Ireland) stock FAQ
What is STERIS plc (Ireland)’s market cap?
STERIS plc (Ireland)’s market cap is $20.56B at the Sep 28, 2026 close of $211.00, with 97.50M shares outstanding. The shares trade on a P/E ratio of 25.7.
What is the STERIS plc (Ireland) stock forecast?
The consensus analyst 12-month price target for STERIS plc (Ireland) is $263.12, +24.7% from the last close. Of the 4 firms that rated the stock in the last 90 days, 3 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is STERIS plc (Ireland) stock overvalued or undervalued?
On Gekko’s estimate STERIS plc (Ireland) is undervalued: the Sep 28, 2026 close of $211.00 is 12.1% below Gekko Fair Value of $240.06. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does STERIS plc (Ireland) report earnings next?
STERIS plc (Ireland) is expected to report on Nov 4, 2026, before the market opens (36 days away). Analysts expect earnings of $2.67 per share on revenue of $1.56B. STERIS plc (Ireland) beat the earnings estimate in 6 of its last 8 reports, moving 4.5% on average across the report.
What is STERIS plc (Ireland)’s 52-week high and low?
STERIS plc (Ireland)’s 52-week high is $269.44 and its 52-week low is $195.14; it closed at $211.00 on Sep 28, 2026, −13.6% over the past year.
Is STERIS plc (Ireland) stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (seasonality) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See STERIS plc (Ireland) the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.